VIRACTA THERAPEUTICS INC (VIRX)

US92765F1084 - Common Stock

0.21  0 (-1.87%)

After market: 0.2274 +0.02 (+8.29%)

VIRACTA THERAPEUTICS INC

NASDAQ:VIRX (12/20/2024, 8:00:01 PM)

After market: 0.2274 +0.02 (+8.29%)

0.21

0 (-1.87%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%18.18%
Sales Q2Q%N/A
CRS9.95
6 Month-66.41%
Overview
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)N/A N/A
Ins Owners2.41%
Inst Owners48.83%
Market Cap8.35M
Shares39.74M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts80
Short Float %4.08%
Short Ratio0.59
IPO09-27 2005-09-27
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

VIRX Daily chart

Company Profile

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. The company is headquartered in Cardiff-By-The-Sea, California and currently employs 26 full-time employees. The company went IPO on 2005-09-27. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The firm is also pursuing the application of its Kick and Kill approach in other virus-related cancers.

Company Info

VIRACTA THERAPEUTICS INC

2533 S Coast Hwy 101, Suite 210

Cardiff-by-the-Sea CALIFORNIA 94080

P: 18584008470

CEO: Parvinder Hyare

Employees: 40

Website: https://www.viracta.com/

VIRX News

ChartMill News Image19 days ago - ChartmillTuesday's after hours session: top gainers and losers

Tuesday's after hours session: top gainers and losers

News Imagea month ago - Viracta Therapeutics, Inc.Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

- Reprioritized resources to reduce costs and enhance focus on Nana-val’s development program in relapsed or refractory EBV-positive peripheral T-cell...

News Image4 months ago - Viracta Therapeutics, Inc.Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the...

News Image4 months ago - InvestorPlaceVIRX Stock Earnings: Viracta Therapeutics Beats EPS for Q2 2024

VIRX stock results show that Viracta Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

News Image4 months ago - BusinessInsiderVIRX Stock Earnings: Viracta Therapeutics Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Viracta Therapeutics (NASDAQ:VIRX) just reported results for the second quarter...

News Image4 months ago - InvestorPlaceWhy Is Viracta Therapeutics (VIRX) Stock Up 42% Today?

Viracta Therapeutics stock is up on Wednesday alongside as VIRX investors react to its most recent earnings report and business updates.

VIRX Twits

Here you can normally see the latest stock twits on VIRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example